Novartis set the pace, Roche had to answer
The Swiss pharma tape has been doing what it usually does in earnings season, rewarding the names that can show volume, margin, and guidance discipline in the same breath. Novartis did that on July 21, with core operating profit of $5.94 billion and a forecast left intact, although the market trimmed some of the first pop once the one-off help in the quarter was understood. Roche had to answer against that backdrop, and it did so with a first-half print that was solid rather than flashy, which is often the more useful category in this part of the market.
Roche Holding AG (Roche) reported group sales of CHF 30.4 billion for the first half of 2026, up 6% at constant exchange rates but down 2% in Swiss francs because the currency kept biting reported numbers. Core operating profit rose 10% at CER to CHF 11.9 billion, the core operating margin expanded 1.7 percentage points, and core EPS increased 9% at CER to CHF 10.85. The company also reaffirmed full-year 2026 guidance for mid-single-digit sales growth and high-single-digit core EPS growth at CER. That is the kind of print that keeps a large-cap healthcare name in the conversation without forcing a rerating on its own.
Roche versus Novartis, the Swiss split-screen
The comparison with Novartis matters because the two names sit in the same broad defensive bucket, but they do not trade on the same operating mix. Novartis has been leaning on a cleaner growth narrative and a quarter that beat expectations, while Roche is carrying a heavier diagnostics franchise alongside pharmaceuticals and a currency translation burden that shows up immediately in Swiss francs. If you want the short version, Novartis gave the market a cleaner headline, Roche gave it a sturdier base.
That difference shows up in the numbers. Roche’s pharmaceuticals division grew 6% at CER to CHF 23.6 billion, while diagnostics rose 3% at CER to CHF 6.7 billion, or 6% excluding China pricing reforms. The company is still getting the benefit of innovative medicines momentum, and the diagnostics arm is not dead weight, but it is also not the kind of engine that makes a stock rerate by itself. Novartis, by contrast, is still being judged more directly on pipeline and product mix, which is why its quarter drew a sharper market reaction even after the initial move faded.
Roche’s share price reflected that steadier profile. On July 24, ROG.SW traded at 350.30 CHF, up 0.23% or 0.80 CHF from the prior session. That is not a dramatic move, and it does not need to be. In a sector where investors are still sorting through patent cliffs, pricing pressure, and the next round of pipeline readouts, a large-cap Swiss name that can hold guidance and keep margins moving is doing enough to stay relevant. Novartis may have had the cleaner beat, but Roche is the one with the broader operating base.
What the first-half print says about the business mix
Roche’s pharmaceuticals division did the heavy lifting. CHF 23.6 billion in sales at CER growth of 6% tells you the core drug franchise is still carrying the group, and the margin expansion tells you management is not buying growth at the expense of profitability. Core operating profit rising 10% at CER against 6% sales growth is the kind of spread that matters. It says the business is not just growing, it is converting that growth into earnings at a better rate than revenue alone would suggest.
Diagnostics deserves a separate read because it is where the company’s mix can look less straightforward. CHF 6.7 billion in sales, up 3% at CER, is respectable in isolation. The 6% growth rate excluding China pricing reforms is the more revealing figure, because it shows the underlying business is stronger than the reported line suggests. That matters in a year when investors are already sensitive to pricing pressure and regional distortions. Roche does not need diagnostics to be the star every quarter, but it does need it to avoid becoming a drag. This quarter, it did that.
The currency line is the part that should keep your expectations grounded. Sales were down 2% in Swiss francs even as they rose 6% at CER. That gap is not cosmetic. For a Swiss exporter, it is the difference between a clean headline and a more complicated one. Roche cannot control the franc, and the market knows it. What it can control is whether the underlying business keeps compounding through the translation noise. On that score, the first half was good enough.
